HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries.

Abstract
The aim of this study was to evaluate and compare the effectiveness of N-acetylcysteine (NAC) and liposomally-encapsulated NAC (L-NAC) in ameliorating the hepatotoxic effects of lipopolysaccharide (LPS). LPS, a major cell wall molecule of Gram-negative bacteria and the principal initiator of septic shock, causes liver injury in vivo that is dependent on neutrophils, platelets, and several inflammatory mediators, including tumour necrosis factor-alpha (TNF-alpha). Male Sprague-Dawley rats were pretreated intravenously with saline, plain liposomes (dipalmitoylphosphatidylcholine [DPPC]), NAC (25 mg/kg body weight), or L-NAC (25 mg/kg NAC body weight) and 4 h later were challenged intravenously with LPS (Escherichia coli O111:B4, 1.0 mg/kg body weight); animals were killed 20 h post-LPS challenge. Hepatic cell injury was evaluated by measuring the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities in plasma. LPS-induced activation of the inflammatory response was evaluated by measuring the levels of myeloperoxidase activity and chloramine concentration in liver homogenates as well as TNF-alpha levels in plasma. The hepatic levels of lipid peroxidation products and non-protein thiols (NPSH) were used to assess the extent of involvement of oxidative stress mechanisms. In general, challenge of animals with LPS resulted in hepatic injuries, activation of the inflammatory response, decreases in NPSH levels and increases in the levels of lipid peroxidation products (malondialdehyde and 4-hydroxyalkenals). Pretreatment of animals with NAC or empty liposomes did not have any significant protective effect against LPS-induced hepatotoxicity. On the other hand, pretreatment of animals with an equivalent dose of L-NAC conferred protection against the liver injuries induced following LPS challenge. These data suggest that NAC when delivered as a liposomal formulation is a potentially more effective prophylactic pharmacological agent in alleviating LPS-induced liver injuries.
AuthorsMisagh Alipour, Abdelwahab Omri, Milton G Smith, Zacharias E Suntres
JournalJournal of endotoxin research (J Endotoxin Res) Vol. 13 Issue 5 Pg. 297-304 ( 2007) ISSN: 0968-0519 [Print] United States
PMID17986488 (Publication Type: Journal Article)
Chemical References
  • Chloramines
  • Lipopolysaccharides
  • N-acetylcysteine lysinate
  • Sulfhydryl Compounds
  • Tumor Necrosis Factor-alpha
  • Peroxidase
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Lysine
  • chloramine
  • Acetylcysteine
Topics
  • Acetylcysteine (analogs & derivatives, pharmacology)
  • Alanine Transaminase (blood)
  • Animals
  • Aspartate Aminotransferases (blood)
  • Body Weight
  • Chloramines (analysis)
  • Disease Models, Animal
  • Lipid Peroxidation (drug effects, immunology)
  • Lipopolysaccharides (administration & dosage, antagonists & inhibitors)
  • Liver (drug effects, enzymology, injuries)
  • Lysine (analogs & derivatives, pharmacology)
  • Male
  • Organ Size
  • Peroxidase (analysis)
  • Rats
  • Rats, Sprague-Dawley
  • Sulfhydryl Compounds (immunology)
  • Tumor Necrosis Factor-alpha (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: